# KRT10 (Human) Recombinant Protein (Q01)

Catalog # H00003858-Q01 Size 25 ug, 10 ug

# Applications



Specification	
Product Description	Human KRT10 partial ORF ( NP_000412, 345 a.a 454 a.a.) recombinant protein with GST-tag at N -terminal.
Sequence	KELTTEIDNNIEQISSYKSEITELRRNVQALEIELQSQLALKQSLEASLAETEGRYCVQLSQIQAQISA LEEQLQQIRAETECQNTEYQQLLDIKIRLENEIQTYRSLLE
Host	Wheat Germ (in vitro)
Theoretical MW (kDa)	37.84
Preparation Method	in vitro wheat germ expression system
Purification	Glutathione Sepharose 4 Fast Flow
Quality Control Testing	12.5% SDS-PAGE Stained with Coomassie Blue.
Storage Buffer	50 mM Tris-HCI, 10 mM reduced Glutathione, pH=8.0 in the elution buffer.
Storage Instruction	Store at -80°C. Aliquot to avoid repeated freezing and thawing.
Note	Best use within three months from the date of receipt of this protein.

### Applications

Copyright © 2023 Abnova Corporation. All Rights Reserved.



- Enzyme-linked Immunoabsorbent Assay
- Western Blot (Recombinant protein)
- Antibody Production
- Protein Array

### Gene Info — KRT10

Entrez GenelD	<u>3858</u>
GeneBank Accession#	<u>NM_000421</u>
Protein Accession#	<u>NP_000412</u>
Gene Name	KRT10
Gene Alias	СК10, К10, КРР
Gene Description	keratin 10
Omim ID	<u>113800 148080 600648 607602</u>
Gene Ontology	<u>Hyperlink</u>
Gene Summary	This gene encodes a member of the type I (acidic) cytokeratin family, which belongs to the superf amily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermol ytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosom e 17q21. [provided by RefSeq
Other Designations	cytokeratin 10

# Publication Reference



• <u>A novel highly reactive Fab antibody for breast cancer tissue diagnostics and staging also discriminates a</u> subset of good prognostic triple-negative breast cancers.

Araujo TG, Paiva CE, Rocha RM, Maia YC, Sena AA, Ueira-Vieira C, Carneiro AP, Almeida JF, de Faria PR, Santos DW, Calabria L, Alcantara TM, Soares FA, Goulart LR.

Cancer Letters 2014 Feb; 343(2):275.

Application: ELISA, FabC4